Chitosan hydrogel for mono-dose treatment of OA, at the 2015 Meeting of the American College of Rheumatology in San Francisco

ACR 2015-logo2

05.11.2015

On November 9, 2015,   at   the  ACR/ARHP Annual  Meeting  in San Francisco, Prof. Yves Henrotin will present new results confirming  the  high  potential  of  the  mono-dose  intra-articular  treatment  with   chitosan  viscoelastic  gels  specifically designed to protect cartilage and decrease the symptoms associated with OA.

#1150 “Novel Chitosan Hydrogels for the Treatment of Osteoarthritis: Mechanical Support, Lubrication and Prevention of Cartilage Degradation in a Rabbit Model of Osteoarthritis.”

Interested in our product pipeline for the treatment of osteoarthritis ? We will be happy to discuss partnership opportunities. Please email us at: contact@synolyne-pharma.com.